 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
20 News |  |
- | PRN1371 / Sanofi, Lytgobi (futibatinib) / Otsuka
Journal: Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. (Pubmed Central) - Jan 26, 2023
In addition, the co-crystal structures of SRC/FIIN-2, SRC/TAS-120 and FGFR4/PRN1371 complexes reveal structural basis for kinase targeting and gatekeeper mutations. Taken together, our study not only provides insight into the potency and selectivity of covalent pan-FGFR inhibitors, but also sheds light on the development of next-generation FGFR covalent inhibitors with high potency, high selectivity, and stronger ability to overcome gatekeeper mutations.
- || Review, Journal: The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. (Pubmed Central) - Jan 6, 2021
Nintedanib, pazopanib, pemigatinib, rogaratinib, fisogatinib, and PRN1371 are FGFR inhibitors lacking drug-enzyme crystal structures...The development of FGFR inhibitors has lagged behind those of other receptor protein-tyrosine kinases. However, the FDA approval of erdafitinib for the treatment of urinary bladder cancers may stimulate additional work targeting the many other FGFR-driven neoplasms.
- ||| PRN1371 / Sanofi
Trial completion date, Trial termination, Trial primary completion date, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Aug 21, 2020
P1, N=45, Terminated, Sponsor: Principia Biopharma Inc.
However, the FDA approval of erdafitinib for the treatment of urinary bladder cancers may stimulate additional work targeting the many other FGFR-driven neoplasms. Trial completion date: Feb 2021 --> Jun 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jun 2020; focus portfolio on immune-mediated diseases
- || PRN1371 / Sanofi
Enrollment closed, Enrollment change, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Mar 4, 2020
P1, N=9, Active, not recruiting, Sponsor: Principia Biopharma Inc.
Trial completion date: Feb 2021 --> Jun 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jun 2020; focus portfolio on immune-mediated diseases Recruiting --> Active, not recruiting | N=50 --> 9
- | PRN1371 / Sanofi
Enrollment open, Trial completion date, Trial primary completion date, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Jan 30, 2019
P1, N=50, Recruiting, Sponsor: Principia Biopharma Inc.
Recruiting --> Active, not recruiting | N=50 --> 9 Active, not recruiting --> Recruiting | Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- | PRN1371 / Sanofi
Enrollment closed, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Sep 4, 2018
P1, N=50, Active, not recruiting, Sponsor: Principia Biopharma, Inc.
Active, not recruiting --> Recruiting | Trial completion date: Dec 2019 --> Feb 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Active, not recruiting
- PRN1371 / Sanofi
Trial primary completion date, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Nov 24, 2017
P1, N=50, Recruiting, Sponsor: Principia Biopharma, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2018 --> Dec 2019
- PRN1371 / Sanofi
Trial primary completion date, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Oct 4, 2017
P1, N=50, Recruiting, Sponsor: Principia Biopharma, Inc.
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Aug 2017 --> Dec 2018
- PRN1371 / Sanofi
New P1 trial, Metastases: A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Nov 18, 2015
P1, N=50, Recruiting, Sponsor: Principia Biopharma, Inc.